All Updates

All Updates

icon
Filter
Product updates
SOPHiA GENETICS launches residual acute myeloid application for post-remission monitoring
Precision Medicine
Jun 24, 2024
This week:
Partnerships
MGI Tech and Predica Diagnostics collaborate to develop Predica's targeted RNA sequencing tests
Precision Medicine
Yesterday
Partnerships
Renalytix partners with Steno Diabetes Center to advance precision medicine solutions for diabetes and chronic kidney disease
Precision Medicine
Yesterday
Partnerships
Myriad Genetics and Personalis cross-license patents for tumor-informed cancer treatment tests
Precision Medicine
Yesterday
Funding
Element Biosciences raises USD 277 million in Series D funding to commercialize AVITI DNA sequencer and support AVITI24 launch
Precision Medicine
Yesterday
Funding
Jacobi Robotics raises USD 5 million in seed funding to expand capacity
Smart Factory
Yesterday
M&A
Formlabs acquires Micronics for undisclosed sum to develop next-generation SLS printers
Additive Manufacturing
Yesterday
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
Precision Medicine

Precision Medicine

Jun 24, 2024

SOPHiA GENETICS launches residual acute myeloid application for post-remission monitoring

Product updates

  • SOPHiA GENETICS has launched the residual acute myeloid (RAM) Application to its SOPHiA DDM platform. The new solution strengthens the company's oncology portfolio with measurable residual disease (MRD) testing capabilities.

  • The RAM Application uses next-generation sequencing (NGS) technology, for post-remission monitoring and identifying early relapse in acute myeloid leukemia (AML) patients. This application leverages the analytical capabilities of the SOPHiA DDM Platform. It is claimed to enable sensitive variant detection down to 0.01% VAF, covering guideline-recommended genes to deliver insights for residual acute myeloid. The solution also offers customizable reporting features and comprehensive MRD reports and leverages machine learning for accurate results within four days.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.